Cytochrome P450 family 4 subfamily A member 32 (CYP4A32)

Cytochrome P450 4A32 (CYP4A32) is a microsomal enzyme belonging to the CYP4 family, primarily expressed in the liver and kidneys of mice [1, 2]. It functions as a fatty acid omega-hydroxylase, catalyzing the oxidation of medium- and long-chain fatty acids, such as lauric acid and arachidonic acid [2, 7]. A key product of its activity is 20-hydroxyeicosatetraenoic acid (20-HETE), a potent lipid mediator that regulates vascular tone and renal sodium transport [7, 8]. In humans, the orthologous functions are performed by CYP4A11 and CYP4A22, which are linked to the development of hypertension and cardiovascular diseases [2, 9]. Research into CYP4A32 often utilizes inhibitors like HET0016 to study the role of 20-HETE in physiological and pathological states, including metabolic syndrome and inflammation [17, 20]. While not a primary drug-metabolizing enzyme for xenobiotics, its role in endogenous lipid signaling makes it a target of interest for therapeutic intervention in renal and cardiovascular disorders [23, 24]. The enzyme is also induced by PPAR-alpha agonists such as fibrates, which can alter fatty acid metabolism and 20-HETE levels [22, 28]. Understanding CYP4A32 is crucial for translating findings from mouse models to human cardiovascular and metabolic therapies [25, 26].

Other names

Cyp4a32Cytochrome P450 4A32P450 4A32Cytochrome P450, family 4, subfamily a, polypeptide 32

Inhibition of omega-hydroxylase activity to reduce the production of the vasoconstrictor 20-HETE; Induction of enzyme expression via PPAR-alpha activation.